Home

Ending the era of untreatable disease


Precision oral medicines targeting the root causes of the world’s most devastating diseases

Unlocking undrugged targets and addressing known targets in novel ways

For decades, many disease-relevant targets were considered beyond the reach of traditional drug discovery. At Totus Medicines, we are changing this paradigm. Through our proprietary OmniDEL discovery platform, we have redefined what is possible — advancing powerful small-molecule therapies against historically ​“undruggable” targets, narrowing the gap from groundbreak­ing science to transforma­tive patient impact.

We are developing precision covalent small molecules with class-leading safety

01 EFFICACY

Covalent molecules serve as a universal key to unlocking undruggable targets for both non-covalent and covalent drug development. Many of the most effective therapeutics in history, including penicillin, AZT, and many lifechanging oncology drugs were developed through this approach.

02 SELECTIVITY

Totus’ OmniDEL Platform uniquely screens targets in their normal cellular environment , allowing us to select the most powerful molecules against a catalog of underserved targets across therapeutic areas of interest.

03 PATIENT IMPACT

We are advancing a new generation of precision oral medicines for patients with limited treatment options, spanning from oncology, immunology & inflammation (I&I), and beyond.

What’s new at Totus